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A B S T R A C T
The Russian Federation prohibited the distribution of herbal mixtures with synthetic aminoalkylindoles 
JWH-018 and JWH-073, agonist cannabinoid receptors, on January 22,2010. The lack or low content of 
their native compounds in urine requires detailed identification of their metabolites, which are excreted 
with urine and are present in blood. Using gas and liquid chromatography-mass spectrometry, we iden-
------------------------------- tified a series of metabolites in urine samples from humans and rats that were products of the following
Iw h  oi« reactions: (a) mono- and dihydroxylation of the parent compounds with hydroxyl groups located at
WH 073 aromatic and aliphatic residues, (b)carboxylation.(c) N-dealkylation and (d) N-dealkylation and hydrox-
Herhtii mixture ylation. The prevailing urinary metabolites in humans are monohydroxylated forms, while N-dealkylated
Metabolites and N-dealkyl monohydroxylated forms are found in rats.Twenty-six samples of herbal smoking mixtures
cc-MS with JWH-018, purchased in Russia, were analysed.
I.C-MS
1. Introduction
The search for compounds possessing high affinity to cannabi­
noid receptors CBi and CB2 led to the synthesis of a series of 
aminoalkylindoles and studies of their pharmacological activity
[1]. High-affinity compounds from naphthalen-l-yl-(l-pentyl- 
lH-indol-3-yl)methanone (JWH-018) and its butyl homologue 
JWH-073 were reported in 1998 [2]. The affinity of these com­
pounds to CB| receptors (located mainly in the central nervous 
system and associated with the generation of a psychoactive 
response) is rather high (affinity constant Kj = 9nM and 8.9 nM 
for JWH-018 and JWH-073, respectively). These compounds 
showed about four times more potent affinity than did Д9- 
tetrahydrocannabinol (К, =41 nM), a psychoactive ingredient in 
marijuana [3.18].
The herbal mixtures made from exotic plant components 
(according to the labels on the packages) and called "spices" 
entered the market in 2004 [4]. These mixtures create marijuana­
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like effects when smoking them, although they contain neither 
Д9-tetrahydrocannabinol nor any other known psychoactive sub­
stances. The increased popularity of these mixtures in Western 
Europe has attracted much public attention and has consequently 
resulted in the study of their chemical composition. In December 
of 2008, THC Pharma (Germany) and AGES PharmMed (Austria) 
independently reported the detection of the synthetic component 
JWH-018 sprayed onto an herbal foundation in a number of these 
mixtures [5]. This result was confirmed by additional studies in 
Western Europe [6,7] and Japan [8,9]. The direct linkage between 
JWH-018 and the psychotropic effects caused by smoking the JWH- 
01 8-containing "spices'’ was established in [10].
The analysis of smoking mixtures, conducted by 
chromatography-mass spectrometry, revealed additional compo­
nents, which were plant-based or added to the mixtures to modify 
their properties. Except for phytosterols, several aromatic additives 
(ethylvanilin, eugenol and eucalyptol), a-tocopherol and oleamide 
[6,9] were detected. The quantitative analysis of fifteen smoking 
mixtures showed that the average concentration of JWH-018 is ca. 
15 mg/g of a mixture [9]. Products with high JWH-073 content are 
extremely rare. This compound occurs in mixtures as an impurity 
(or additive) [7,9]. According to several messages in specialised
Table 1
List of components found in smoke mixtures with active JWH-018.
Product JWH-018 JWH-073 CP 47. 497 C8 Tocopherol Other substances
Afghan incense +++ + — + —
Chernobyl +++ ♦ + ♦ JWH-018 (-CI)4
Genie blend ++ - - -
Master Kush +++ - - ■f -
Mojo ++ - - +++ -
Smoke ++ - + + Eugenol, oleamide(main component)
Spice arctic synergy ++ - ++ +++ Menthol, JWH-018 (-C1)*1
Spice diamond + (trace) - ♦+ +++ Ethylvanillin
Spice tropical synergy ++ + ++ +♦+ Menthol, caffeine
Yucatan fire ++ ++ +++ —
Unnamed Mixture 1 +++ - - +++ -
Unnamed Mixture 2 + - +++ + -
Unnamed Mixture 3 +++ + - - Menthol
Unnamed Mixture 4 +++ ++ - + -
Unnamed Mixture 5 +++ - - - Nicotine, 1-pentyl-IH-indole, pentyl 1-naphthoate
Unnamed Mixture 6 +++ + - - 1-pentyl-lH-indole
Unnamed Mixture 7 +++ - - - Nicotine
Unnamed Mixture 8 ++ - - +++ -
Unnamed Mixture 9 ++ - + +++ -
Unnamed Mixture 10 +++ - - - Oleamide
Unnamed Mixture 11 +++ + - - Vanilin 1-pentyl-1H-indole
Unnamed Mixture 12 +++ - - - -
Unnamed Mixture 13 ++ - + -
Unnamed Mixture 14 +++ + - ++ -
Unnamed Mixture 15 +-H- - - - -
Unnamed Mixture 16 +++ — - Menthol, nicotine, indole. 1-pentyl-IH-indole, pentyl 
1-naphthoate, 1-naphthamide
J Chlorinated JWH-018 components.
internet forums (and instructions on the use of smoking mixtures), 
80-150 mg of these mixtures, corresponding to approximately 
1-2.5 mg of JWH-018, must be smoked to induce psychogenic 
effects. The actual quantity absorbed by the lungs is significantly 
lower.
JWH-018 intake can be established by detecting the 
native compound in blood [11-13]. For this purpose, liquid 
chromatography-mass spectroscopy (LC-MS) and high-sensitivity 
MS methods were used to detect JWH-018 at concentrations of 
ng/mL and lower. The compound concentration in a smoker's 
serum decreases rapidly (90% of the maximal concentration has 
dissipated within three hours after smoking) [11].
JWH-018 and JWH-073 are poorly soluble in water and produce 
no hydrophilic conjugates. The first study of the metabolism of sim­
ilar compounds were performed in vitro and showed that the main 
metabolic pathways of these compounds might be hydroxylation 
and N-dealkylation of the parent compound [14]. The authors in
[15] reported the results of urine analyses of rats that had JWH-018 
introduced by intragastric intubation. Although the native com­
pound was found in the urine, the authors noted the prevailing
content of the hydroxylated N-dealkylated forms. In a study on the 
identification of JWH-018 metabolites in human urine, hydroxyla­
tion of the initial structure was proposed as the main metabolic 
pathway; however, N-dealkylated metabolites were also found
[16]. No native JWH-018 was observed in three human urine sam­
ples, which is a significant result of the study.
The aim of this study is to identify JWH-018 and JWH-073 
metabolites as markers of JWH-018 and JWH-073 use by gas and 
liquid chromatography-mass spectrometry. Eleven urine samples 
from humans who took synthetic cannabinoids and four rat urine 
samples were analysed. In addition, a review of smoking mixtures 
with JWH-018 (and JWH-073) purchased in Russia is provided.
2. Materials and methods
2.1. Reagents
N,0-bis(trimethylsilyl)trifluoroacetamide with 1% 
trimethylchlorosilane (BSTFA + 1% TMCS) was purchased from 
Acros Organics (Ceel, Belgium), pyridine (analytical grade) was
M13. M14 M1 (JWH 073)
Fig. 1. The proposed structures of the identified JWH-018 metabolites.
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Fig. 2. Fragments of ion chromatograms of urinary JWH-018 metabolites (TMS). SCAN mode.
purchased from Scharlau Chemie S.A. (Barselona, Spain), and 
acetonitrile and methanol were supplied by Panreac Quimica 
S.A. (HPLC-gradient grade). The other solvents and chemicals (for 
analysis) were obtained from Ecos-1 (Moscow, Russia). Solid-phase 
extraction cartridges, AccuBond SPE ODS-C18 (3mLx200mg), 
were supplied by Agilent Technologies (Santa Clara, CA, USA).
The immunochromatographic assays were applied to test strips 
(ICA-4-MULTI-FACT0R, 1CA-MARIJUANA-FACTOR and ICA-TAD- 
FACTOR) supplied by Factor-Med (Moscow, Russia).
2.2. Herbal smoking mixtures and their processing
Twenty-six smoking mixtures (Table 1) with different labels (or 
without labels) were purchased via the internet from July 2009 to 
January 2010. The weight of these herbal products varied from 0.5 
to 5g.
The smoking mixtures (10-30 mg) were crushed into powder 
and extracted with 3 mLof ethanol under ultrasonication for 10 min 
at room temperature to extract the sprayed compounds. The extract 
was then centrifuged and filtered through 0.45 fjim filters (Milli- 
pore, Bedford, MA). The extracts were analysed by GC-MS.
Unnamed Mixture 4. containing (apart from JWH-018) a consid­
erable amount of JWH-073, was used to studyJWH-018 metabolism 
in rats. Five grams of this mixture was extracted twice with ethanol 
(2xl00m L) under ultrasonication. After filtration, the solution 
was evaporated in a vacuum rotary evaporator. The resulting tarry 
residue (TR, about 110 mg) was applied to study the metabolism of 
the active components without any further purification.
2.3. Urine samples (of drug-intoxicated persons detained by 
police)
The urine samples were collected from eleven individuals with 
symptoms of drug intoxication who were brought to the drug ser­
vice by police and confessed to having smoked herbal mixtures. 
No common drugs were found by immunochromatographic assay 
(including detection of cannabinoids, benzodiazepines, morphine, 
cocaine and amphetamines).
2.4. Experimental procedures with rats
The TR suspension in 2% Tween-80 was intraperitoneally intro­
duced into four Wistar rats after a day without feeding at a rate of 
15 and 30 mg ofTR/kg of body mass (that corresponds to approx­
imately 0.7-1.4g of the original smoking mixture). Symptoms of 
suspension influence are typical for cannabinoids cataleptic activity
[17]. Three hours after suspension introduction, the animals were 
placed in metabolic pans for 20 h with free access to water to collect
their urine. An additional rat was given a placebo (2% Tween-80 in 
water) to obtain a blank urine sample.
2.5. Preparation of urine samples
Liquid-liquid extraction (LLE) and solid-phase extraction (SPE) 
were used for the preparation of the urine samples.
For LLE, 2.5 mL of urine was added to 0.3 mL of hydrochloric 
acid (ca. 30%) and heated at 90-95 С for 60 min. After cooling, 
aqueous ammonia (ca. 25%) was added to reach a pH of 8-9. The 
samples were extracted with 3 mL of chloroform and centrifuged. 
The organic phase was evaporated by nitrogen stream at 45 С or 
below. The dry residue was dissolved either in 50 |jlL of ethanol (for 
GC) or in the same volume of 10% v/v acetonitrile in water (for LC).
For SPE, the sample (3 mL of hydrolysed urine, pH 8-9 plus 3 mL 
of water and 0.6 mLof acetonitrile) was loaded onto a cartridge. The 
sorbent was rinsed by 10 and 40% v/v acetonitrile in water (3mL) 
and dried by air stream for 30 s. The analytes eluted 3 mL of acetone. 
The recovery was determined by adding an extract with high con­
centrations of the components to the blank hydrolysed urine. For 
three measurements, the average recovery was 102% (RSD 10%).
Derivatisation of the samples for GC was performed by 
trimethylsilylation (TMS), acetylation (AC) or trifluoroacetylation 
(TFA). TMS was carried out in a mixture of BSTFA and ethyl acetate, 
25 p.L each, at 60 С for 60 min. For acetylation, the dry residual was 
dissolved in the mixture of acetic anhydride and pyridine, 50 p.L 
each, and heated at 70 С for 30 min. Then the mixture was evap­
orated in the vacuum concentrator (Concentrator 5301, Eppendorf 
AG, Hamburg, Germany) and dissolved in 50 jiL of ethanol. The TFA 
derivatives were prepared in a mix of trifluoroacetic anhydride and 
ethyl acetate, 50 |jlL each (50 C, 30 min). After evaporation, the dry 
residual was dissolved in 50 fiL of ethyl acetate.
2.6. GC-MS
Gas chromatographs 6890 connected to single-quadrupole 
mass spectrometers 5973 and 5975VL were equipped 
with HP-5ms (30 m x 0.25 mm x 0.25 jim) and EVDX-5ms 
(25 m x 0.20 mm x 0.33 p,m) columns (Agilent Technologies). 
The separation was performed by applying the following tempera­
ture program: 50 С (0.5 min), 99 /min (100 С, 1 min), and 60=/min 
(320 C, 15 min). Helium was the carrier gas (1 and 0.8mL/min 
for both columns, respectively). The column temperature was 
reduced for the acquisition of spectra of poorly separated com­
pounds (35 C/min and 300 С at the last steps). The sample (1 (jlL) 
was injected in splitless mode (270 C). The temperatures of the 
transfer line, ion source (electron ionisation mode, 70 eV) and mass 
filter were 290, 230 and 150 C, respectively. The mass spectra
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Fig. 3. Mass spectra ofJWH-018 (a) and its main metabolite M l (b).
Fig. 4. Mass spectra of Ml after derivatisation by TMS (a) and AC (b).
Table 2
Linear relenlion indices (n-alkanoic scale, [:VDX5ms column) and occurrence of detected metabolites.
No. Compound Net formula I M f Index Detection
Human Rat
1 JW II 018 Cm Hj j NO 341 3316
2 Ml Cm Hj j NOj 357 3543 ♦
3 Ml TMS C,7ll„N O ,Si 429 3498
4 Ml AC C26H2;,NOj 399 3580
5 M1TPA C26H22F,NOj 453 3328
6 M 1 TFA/artefact c24h2,no 339 —3313
7 М2 TMS C27H3|NO,Si 429 3591 ♦-
8 М2 AC C26M25NO, 399 3702
9 М2ТГА C,,,ll« Г< N< >( 453 3454
10 М3 TMS O 7I In NU?Si 429 3571 ♦- -
11 M4 TMS Cj/HjiNC^Si 429 355/ ♦ -
12 M5 I MS Cj,HMN03Si 443 3689 ♦ -
13 M5 Me C^HaNOj 385 3630
И M6 2TMS CwllwNCbSh 517 3699 ♦
15 M7 2TMS C30H,9NO,Sb 517 3735 ♦ -
16 M8 2TMS Cm Hjs NOj SIj 517 3735 ♦ -
17 M9 21 MS с ,011 t;‘N( lt Si, 517 3752 ♦ -
18 М10ЛС c2Ih I5no , 313 3129 ♦
19 M il 2AC C2j H „N 04 371 3451 ♦ ♦
20 M12 2ЛС c23h „n o 4 371 3493 ♦ ♦
21 М13 2ЛС Cjt I I ,; N(l< 371 3499 ■f ♦
22 М14 2ЛС C23Hi7N04 371 3479
23 JW II 073 c23h„ n o 327 37-34
24 Ml (JWH 073)TMS C2g IbiiNl >7 Si 415 339/ ♦
25 Ml (JWH 0/3) AC C25H23NOj 385 34/8
of the identified components were background, corrected by the 
AMDIS (automatic mass spectral deconvolution and identification 
system) program (NIST, USA] in manual and auto modes. Variations 
in intensity of the most critical m/z values were checked in selected 
ion monitoring (SIM) mode.
2.7. LC-MS/MS (Q-TOF)
The liquid chromatograph 1200 in tandem with a 6510 
quadrupole - time-of-flight (Q-TOF) mass spectrometer and 
Chip Cube ionisation source (Agilent Technologies) was used in 
nanoflow mode. The separation was performed on a HPLC-Chip 
(Agilent) containing enriching (Zorbax 80SB-C18,40 nL, 5 (j,m) and 
analytical (Zorbax 80SB-C18,75 |xm 43 mm, 5 (j,m) columns. The 
enriching column was loaded and washed with 0.1% formic acid in 
water (3 jiL/min). The sample components were eluted by a linear 
gradient with a mobile phase A (0.1% formic acid in water) and В 
(20% v/v phase A in acetonitrile) from 2 to 100% of phase В for 48 min 
and held with the final solution over 2 min. The mobile phase flow 
rate was 0.4|xL/min.
MS/MS-analysis was made by electrospray ionisation (ESI) and 
positive ion detection. The temperature of the drying gas (nitrogen, 
flow rate 5 L/min) was 325 С at a capillary voltage of 2000 V. The 
scanning range was from 100 to 1000 Da, and auto MS/MS com­
ponents search mode (registration of precursor and product ions 
spectra) with Agilent MassHunter workstation software was used.
2.8. LC-MS/MS (QqQ)
This method was used in the product ion scan and selected reac­
tion monitoring (SRM) modes.The liquid micro-column chromato­
graph Milichrom A-02 (Econova, Russia) with 2.1 mm < 75 mm 
column (ProntoSIL-120-5-C8 AQ; Bischoff Chromatography, Leon- 
berg, Germany) was connected to SCIEX API 365 triple-quadrupole 
mass spectrometer (AB Sciex, Foster City, CA, USA) in positive ESI 
mode. AB Sciex Analyst workstation software was used.The follow­
ing gradient system was used with mobile phase A (0.1% v/v formic 
acid in water) and В (methanol) delivered at 0.1 mL/min: from 2% 
to 100% of solvent В within 30 min and then solvent В for 2 min.
3. Results and discussion
3.1. Smoking mixtures composition
The Russian market for smoking mixtures is distinguished by 
the diversity of available products. Originally, smoking mixtures 
were imported to Russia under known trademarks, and their com­
position corresponded to the published data [6-9]. The relative 
simplicity of the mixture-making procedure as well as the qual­
ity and variety of the ingredients resulted in a large number of 
home-made products. These products were then sold under Rus­
sian trademarks (or not marked) via the internet or anonymous 
distribution networks. The publication of synthetic formulas in sci­
entific journals facilitated the synthesis of JWH-018 at home or in 
a small laboratory. The prohibition of JWH-018 in Russia (effective 
as of January 22,2010) has led to sales of sets of legal components, 
allowing home-made JWH-018 synthesis. Therefore, the compo­
sition of the smoking mixture eventually became dependent on a 
particular maker's (seller's) capacities, personal features and mix­
ture history (Table 1).
The components extracted from smoking mixtures can be 
divided into five groups.
(1) Psychoactive components added to a mixture according to 
the adopted technology or while making or using the product 
(homologous aminoalkylindolesJWH-018, JWH-073 andcyclo- 
hexylphenol CP-47, 497 C8 (2-[(lR,3S)-3-hydroxycyclohexyl]- 
5-(-2-methyloctan-2-yI)phenol, C22H.16O2 ) [6]).
(2) Ingredients improving or modifying the quality of a product. 
Tocopherol is present in nearly all of the considered mixtures 
and is probably added as an antioxidant. Tocopherol is the main 
ingredient observed in "Genie Blend”, “Mojo”, “Spice Arctic 
Synergy”, “Spice Diamond". "Spice Tropical Synergy", "Yucatan 
Fire" and Unnamed Mixtures 8, 9 and 13 (based on the GC 
method). Oleamide, which apparently modifies the psychoac- 
rivity of aminoalkylindoles, is rare. "Smoke” (except oleamide 
with a prevailing concentration) also contains considerable 
amounts of saturated and unsaturated amides Сц-Сго-
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Fig. 5. Pyrolysis of M l TFA in chromatography column.
(3) Aromatic additives (eugenol, menthol and vanillin 
derivatives).
(4) Numerous substances typical of an herbal basis for a mixture, 
including nicotine.
(5) Possible synthesis of half- or by-products of active com­
ponents and impurities (indole, 1 -pentyl-IH-indole, pentyl 
1-naphthoate and 1-naphthamide). Atypical impurities were 
found in "Chernobyl” and "Spice Arctic Synergy" and identi­
fied as substances containing chlorine atoms in the JWH-018 
naphthalene residue. In total, two similar components are 
detected, and it is impossible to state whether one of 
them is identical to the known chlorinated aminoalkylindole 
of JWH-398 ((4-chloronaphthalen-l-yl)(l-pentyl-lH-indol-3- 
yl)methanone, C24H22CINO) [3].
The original mixture composition can be distorted by the chem­
ical degradation of its components. Our observations show that 
for an allegedly home-made mixture (Unnamed Mixture 3, with­
out tocopherol) that had been stored about one month at room 
temperature, JWH-018 almost completely disappeared. Neverthe­
less, monitoring of Unnamed Mixture 4 (an alcoholic extract) that 
was stored in a room for stability assessment did not result in any
decrease in concentration of aminoalkylindoles within at least a 
month.
3.2. GC-MS: urine samples from rats and humans
JWH-018 and JWH-073 metabolites were searched and identi­
fied mainly by GC-MS. For this purpose, all of the samples described 
in the experimental section were used. The spectra specified in this 
subsection were obtained by electron ionisation. No investigated 
urine sample showed native JWH-018 and JWH-073. These results 
are consistent with earlier observations [ 16] but contradict another 
study [15]. Such disagreement may have two reasons: (1) the low 
solubility of JWH-018 (according to our evaluation) in water and (2) 
the application of more sensitive analytical method (LC-MS/MS) by 
the authors [15]. Due to its structural features, JWH-018 cannot be 
conjugated by urea acids (as a native compound) and is therefore 
excreted as a water-soluble conjugate. Application of more sen­
sitive methods of analysis could make it possible to detect trace 
concentrations of JWH-018 in human urine.
The search and identification of metabolites was based on gen­
eral assumptions about the probable metabolic pathways of similar 
compounds, which suggested oxidation and N-dealkylation of the 
parent structure, and on conclusions from previous investigations 
[14-16]. Fourteen JWH-018 metabolites were found in human and 
rat urine samples. Their proposed structures are shown in Fig. 1. 
The linear retention indices and the occurrence of the studied com­
pounds in the human and rat urine samples are given in Table 2.
The physiological activity of new compounds is generally first 
studied in laboratory animals. For this study, we can conclude 
that the general metabolic pathway of rats and humans differs. 
Only N-dealkylated (and N-dealkylated with monohydroxylation) 
metabolites were found in rat urine. The human urine samples 
showed a prevalence of primary and secondary hydroxylation 
products, and the content of N-dealkylated forms was insignificant 
upon routine urine analysis by GC-MS.
According to our estimates, over 90% of the hydroxylated 
metabolites are present in urine as conjugated forms, and 
enzymatic or acid decomposition is therefore required. Sample 
preparation by SPE and LLE isolated nearly identical amounts of 
the matrix compounds in extracts that were associated with rather 
low selectivity by reversed-phase SPE. Therefore, a reduction-of- 
measurements cost was applied to sample preparation by LLE.
The choice of a derivatisation method is a major issue in sam­
ple preparation. The best method of the three applied (TMS, AC, 
TFA), in terms of sensitivity and number of observable metabo­
lites, was TMS. Acetylation is also applicable to routine analyses, 
though the sensitivity is slightly reduced. Trifluoroacetylation can­
not be recommended because some derivatives have low thermal 
stability.
All of the detected metabolites may be structurally divided into 
four groups: monohydroxylation, dihydroxylation, carboxylation 
and N-dealkylation. The identification of each group's compounds 
will be described in the following subsection.
3.2.1. Monohydroxylation (M l-M4)
Ion chromatograms of the JWH-018 metabolites in human urine 
are shown in Fig. 2. The main JWH-018 (and JWH-073) metabolite 
observed under our conditions is the monohydroxylated form of 
M l, and the hydroxyl group is supposed to substitute for one of 
protons on the N-pentyl chain. This assumption corresponds to the 
observations suggesting that the prevailing oxidation occurs at the 
aliphatic part and not the aromatic part of the parent compounds. 
The mass spectrum of M1 is given in Fig. 3. The parent compound 
spectrum is provided for comparison. The spectra of both com­
pounds possess typical ions. Both for the parent compound and 
for M l, the naphthalene residue can be identified by m/z 127 and
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Fig. 6. Mass spectra ofJWH-073 and its monohydroxylated metabolite (TMS).
155. The relevant ions for the indole residue of JWH-018 are 186 
and 214, while similar ions with m/z 202 and 230 for M l suggest 
the presence of hydroxyl groups. Ions with m/z 116 and 144 cor­
respond to dealkylated indole fragments. The proposed location of 
a hydroxyl group on the N-pentyl chain (instead of on the indole 
bicycle) is based on the presence of ions with m/z 144, 116 and 
284 ([Ml** -H20, -C4H7[) and 296 ([Ml** -H20, -C3 H7[) in the 
M l spectrum. Ions with m/z 212 indicate dehydration accompa­
nied by double bond formation. Additional arguments in support 
of the hydroxyl location will be described below.
The mass spectra of the TMS and AC derivatives of M l are given 
in Fig. 4. These spectra are similar to the underivatised M l spec­
trum. For both derivatives, we note the presence of ions with m/z 
184 and 212 formed through the elimination of trimethylsilanol (or 
acetic acid) with double bond formation in the N-pentyl chain, m/z 
296 has the same parentage as underivatised M l.
The pyrolysis of the TFA derivative of Ml (and of some other 
metabolites) in a chromatographic column can serve as additional 
proof of the proposed hydroxyl localisation (Fig. 5). The formed 
chromatographic artefact corresponds to an N-pentenyl analogue 
of JWH-018.
The main metabolite of JWH-073 (observed under our condi­
tions) is apparently a product of side chain monohydroxylation. 
Because JWH-073 is usually present in smoking mixtures in 
small concentrations (compared to JWH-018), detecting its minor 
metabolites is difficult. The parent compound and its metabolite 
spectra (as a TMS derivative) are given in Fig. 6 .
Metabolite М2 (Fig. 7a) is the second mixture component in 
terms of the observable content The mass spectra of its TMS and AC 
derivatives are very similar to the corresponding M l spectra, and 
it may be identified as an isomer due to the location of a hydroxyl 
group in the N-pentyl chain.
The spectrum of the TMS derivative of the М3 metabolite 
(Fig. 7b) contains ions with m/z 127 and 155 (which suggests 
a lack of a hydroxyl group in the naphthalene residue), and it
apparently does not contain m/z 116 and 144 (corresponding 
to a unchanged indole residue). Nevertheless, the intensive m/z 
270 and 284 suggest that this compound is also an Ml isomer 
with regards to the location of a hydroxyl group in the N-pentyl 
chain.
The hydroxyl group of M4 (Fig. 7c) is located in the naphtha­
lene fragment because the spectrum of its TMS derivative contains 
ions with m/z 116, 144 and 214 (unchanged indole residue). The 
formation of m/z 358 and 372 is caused by the fragmentation or 
elimination of the N-pentyl chain.
3.2.2. Carboxylation(M5)
The TMS derivative of a carboxylated metabolite M5 can be iden­
tified by the m/z value for the molecular ion (443) and the presence 
of m/z 127, 144 and 155. A compound appearing in a mixture of 
metabolites afteretherification with methanol in an acidic medium 
would support the given structure. The identified compound was 
a methylate of a carboxylated metabolite M5 (Fig. 8 ). No M5 was 
revealed in a mixture of TMS derivatives by additional derivatisa- 
tion (TMS) after etherification.
3.2.3. Dihydroxylation (M6-M9)
Four strongly retained compounds (M6-M9) contain m/z 517 
(proposed molecular ion) in their spectra and can be referred to 
as dihydroxylated metabolites of JWH-018 (Fig. 9). The interpre­
tation of their structures is complicated due to low concentration 
and poor separation. The lack of ions with m/z 127 and 155 and the 
low intensity of m/z 243 indicate localisation of a hydroxyl group 
on a naphthalene residue that is valid for M7-M9. The ion with m/z 
184 in the spectra of these compounds is formed by the elimina­
tion of trimethylsilanol with multiple bond formation that allows 
interpreting M7-M9 as the products of hydroxylation of the naph­
thalene residue and N-pentyl chain. Metabolites M7 and M8 can be 
partially separated if the column temperature gradient is reduced. 
The spectra of these compounds are generally similar. The intensive
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Fig. 7. Mass spectra of minor monohydroxylated JWH-018 metabolites (TMS).
m/z 127 and 155 is typical for M 6 . In this compound, the hydroxyl 
groups are likely to localise at the indole bicycle and N-pentyl chain. 
For all three compounds, an ion with m/z 358 results from the full 
elimination of a hydroxylated alkyl chain, and the group of ions with 
m/z 372-426 may be explained by multiple bond formation upon 
elimination of trimethylsilanol and the stepwise fragmentation of 
a chain.
3.2.4. Dealkylation (M l0-M I4)
The dealkylated metabolites of JWH-018 were originally iden­
tified in rat urine. These compounds were detectable due to the 
relative compositional simplicity of these samples and the smaller 
matrix influences. The entire group of dealkylated metabolites was 
identified only as AC derivatives because of difficulties with silyla- 
tion, which is related to the specific behaviour of the indole nitrogen 
in these compounds. The simplest member of this group (M10) is 
present at a considerable concentration in rat urine, and it was not 
detected in human urine.
The monohydroxylated forms of depentyl JWH-018 are hardly 
separable under our chromatography conditions but can be satis­
factory separated if the column temperature gradient is reduced. 
A comparison of the fragments from the ion chromatograms for 
the rat and human urine samples is shown in Fig. 10. Metabolites 
M11-M13 are present in both samples, while M14 is in human 
urine only. All of the dealkylated metabolites are present in human 
urine at low concentrations and cannot be detected in the majority 
of the samples.
Except for the location of the hydroxyl groups in the correspond­
ing residue, decoding the structures of these metabolites is not 
problematic. According to the spectra in Fig. 11, M11 and M12 have 
hydroxyl groups located at the naphthalene residue, m/z 127 and
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Fig. 8. Mass spectra of TMS and methyl derivatives of the M5 metabolite.
155 are not present, but intensive 270 and 286, which are formed 
by the elimination of ketene molecules, as well as m/z 144 occurs. 
For M13 and M14, an intensive ion with m/z 160 (naphthalene 
eliminating) indicates that the hydroxyl is localised at the indole 
residue.
m/z
Fig. 9. Mass spectra of dihydroxylated JWH-018 metabolites (TMS), Мб (a), M7 (b) 
and M9(c).
time, min
Fig. 10. Comparison of the allocation of metabolites M l 1-M14 in human (a) and rat 
(b) urine samples. The last steps of the temperature program: 35 C/minand 300 C, 
SIM mode.
3.3. LC-Q-TOF: rat and human urine
Liquid chromatography with a tandem Q-TOF mass spectrom­
eter was used only to confirm the identification of some of the 
discovered metabolites and to clarify their structures (Fig. 12). The 
mass spectra of the JWH-018 product ions(tR - 37.11 min, Fig. 12f) 
contains the same characteristic ions as the spectrum of electron 
ionisation.
The peak with tR about 26.26 min (Fig. 12a and g) is the major 
peak on the chromatogram, registers within 358.1000-358.2000 
and can be identified as metabolite M l (C24H23NO2 ). The differ­
ence between the calculated and measured m/z of the precursor 
ion is 1.60 ppm. The spectrum of the product ions indicates that 
the hydroxyl group is at the indole residue (230.1152, C14H16NO2 ). 
and m/2 284.1061 (C20H14NO, the difference is 3.26 ppm) is a direct 
indication of hydroxylation of the N-alkyl chain. Ml is observed in 
human urine but is nearly absent in rat urine.
The carboxy metabolite M5 is detected in human urine only. The 
spectrum of its precursor ion corresponds to the molecular formula 
C24H21NO3 (difference is -0.73 ppm).
The dihydroxylated metabolites were poorly separated in the 
applied chromatography conditions, and their detailed identifi­
cation is therefore hindered. Nevertheless, the m/z of the single 
precursor ion from the chromatographic band corresponds to the 
gross formula C24H23NO3 (difference is -4.60 ppm). The spectrum 
of product ions registered near the intensity maximum of the chro­
matographic band contain m/z 143.0514 (C 1 0 H7 O) and 171.0459 
(Ci 1H7O2 ), corresponding to the location of the hydroxyl group at 
the naphthalene residue (Fig. 12h). These metabolites are detected 
in human urine only.
The group of the hydroxylated N-dealkyl metabolites detected 
in rats and human urine (Fig. 12d, e and i) is also poorly sep­
arable in the provided conditions. The m/z of the precursor ion
m/z
Fig. 11. Mass spectra of dealkylated metabolites (acetylation).
is consistent with the gross formula C19H13NO2 (difference is 
-7.53 ppm).
3.4. LC-QqQ: human urine
The high cost and rather low sensitivity of LC systems with 
tandem TOF mass spectrometers makes them impractical for rou­
tine analysis. Therefore, a triple-quadrupole mass spectrometer 
was mainly used for the LC analyses of the urine samples. The 
sensitivity of this method is sufficient to properly detect minor 
metabolites after a considerable time following JWH-018 adminis­
tration. Thus, two targets of analysis may be acquired during one 
chromatographic run: establishment and confirmation ofJWH-018 
administration. The chromatograms of human urine samples are 
shown in Fig. 13a-c. Because metabolites with an ion at 155 in the 
spectrum prevail in the mixture and the intensity of this ion in the 
spectra of product ions is high (Fig. 13d—f). transitions [M+H] -<• 155 
were used for SRM mode.
time, min m/z
Fig. 12. Mass chromatograms of human (a-d) and rat (e) urine samples. Mass spectra of product ions of JWH-018 (0 and M l (g). Spectra of M6-M9 (h) and Ml 1-M14 (i) 
registered according to the intensity maxima of the chromatographic band of the chromatogram.
3.5. Comparison of concentrations ofJWH-018 metabolites in 
human urine samples
The relative concentrations of metabolites in urine samples col­
lected from individuals delivered to drug service due to inadequate
behaviour may be of interest. The concentrations of three hetero­
geneous metabolites (M1, M5 and M6 ) in eleven urine samples, 
arranged in decreasing order of M1 concentration, are shown in 
Fig. 14. The analysis was carried out by GC-MS with a sample prepa­
ration, including liquid-liquid extraction and TMS. The molecular
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Fig. 13. SRM chromatograms of human urine (a-с). Product ion spectra ofJWH-18 (d), M1 (e)and M5(f)-
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urine sample, No.
Fig. 14. Concentrations (conventional units) of three metabolites in urine samples 
collected from persons delivered to drug services. The M5 and M6 concentrations 
were multiplied by a factor of 10.
ions of TMS derivatives are intensive for all of the determined com­
pounds, and their peak areas were used as analytical responses. 
The highest M l concentration is about eight times higher than the 
lowest one, which may be due to different time periods between 
JWH-018 administration and urine collection.
4. Conclusion
Fourteen JWH-018 metabolites (hydroxylated, carboxylated 
and dealkylated products) were identified in human and rat 
urine samples. One monohydroxylated metabolite JWH-073 was 
detected in human urine. For JWH-018, the main observable 
components in human and rat urine are the monohydroxylated 
metabolites and the dealkylated with monohydroxylation metabo­
lites, respectively.
Sample preparation by SPE and LLE resulted in nearly identical 
amounts of matrix compounds in the extracts. For the detection 
of minor (dealkylated and dihydroxylated) metabolites in human 
urine, LC-MS/MS was more convenient.
None of the investigated samples showed native JWH-018 
or JWH-073. Therefore, the abusive consumption of synthetic 
cannabimimetics JWH-018 and JWH-073 can only be established 
by the detection of their metabolites in urine by GC-MS and 
LC-MS/MS.
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